tradingkey.logo
tradingkey.logo

Parabilis Medicines’ Zolucatetide Receives FDA Orphan Drug Designation For The Treatment Of Desmoid Tumors

ReutersMar 11, 2026 11:21 AM

- Parabilis Medicine:

  • PARABILIS MEDICINES’ ZOLUCATETIDE, THE FIRST AND ONLY DIRECT INHIBITOR OF THE ELUSIVE Β-CATENIN:TCF INTERACTION, RECEIVES FDA ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF DESMOID TUMORS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI